Last reviewed · How we verify
Sanwa Kagaku Kenkyusho Co., Ltd. — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
1 Phase 3
4 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Cephulac | LACTULOSE | marketed | Osmotic Laxative [EPC] | Infectious Disease | 1976-01-01 | |
| Upasita | UPACICALCET | marketed | Extracellular calcium-sensing receptor | Hematology | ||
| SK-1403 | SK-1403 | phase 3 | Unknown | Unknown | Unknown |
Therapeutic area mix
- Hematology · 1
- Infectious Disease · 1
- Unknown · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Abdi Ibrahim Ilac San. ve Tic A.S. · 1 shared drug class
- Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
- Beijing Tiantan Hospital · 1 shared drug class
- Braintree · 1 shared drug class
- Bursa Yuksek Ihtisas Training and Research Hospital · 1 shared drug class
- Dongkook Pharmaceutical Co., Ltd. · 1 shared drug class
- GlaxoSmithKline · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Sanwa Kagaku Kenkyusho Co., Ltd.:
- Sanwa Kagaku Kenkyusho Co., Ltd. pipeline updates — RSS
- Sanwa Kagaku Kenkyusho Co., Ltd. pipeline updates — Atom
- Sanwa Kagaku Kenkyusho Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Sanwa Kagaku Kenkyusho Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sanwa-kagaku-kenkyusho-co-ltd. Accessed 2026-05-16.